Related Experiment Videos
A double blind, placebo controlled study of a platelet activating factor antagonist in patients with rheumatoid
P Hilliquin1, V Chermat-Izard, C J Menkes
1Institut de Rhumatologie, Hôpital Cochin, Paris, France.
Objective:
To evaluate the efficacy and tolerance of a platelet activating factor-acether (PAF) antagonist, BN 50730, in patients with rheumatoid arthritis (RA).
Methods:
A total of 56 patients with active RA were enrolled in a multicenter, double blind, placebo controlled study of BN 50730. Patients received either BN 50730 (40 mg orally bid) or placebo for 84 days.
Results:
Treatment with BN 50730 resulted in no improvement and was no more effective than placebo in improving clinical and biological indices of RA activity. Adverse events were observed in the 2 treatment groups, and BN 50730 was generally well tolerated.
Conclusion:
PAF antagonist BN 50730 at a daily dose of 80 mg was ineffective in the treatment of RA.